---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-051957"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:46:10.810154+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verrica Q4 product revenue $0.3M, net loss $0.24/sh; YCANTH units up 12.3% sequentially

## Summary
- Q4 product revenue $0.3M (vs $1.9M in 2023); FY product revenue $6.6M (vs $4.7M) with $3.2M returns reserve.
- Q4 GAAP net loss $16.2M ($0.24/sh) vs $24.6M ($0.53/sh); FY loss $76.6M ($1.48/sh) vs $67.0M ($1.48/sh).
- YCANTH dispensed units 8,654 in Q4 (+12.3% QoQ); operating expenses cut ~50% after restructuring with $1.0M charge.
- Cash $46.3M at Dec 31; $8M Torii milestone upon Phase 3 common warts start and $25M Series A warrants could extend runway; GAAP raises going concern doubt.
- VP-315 Phase 2 shows 97% ORR and ~51% complete histological clearance; Phase 3 for common warts could begin mid-2025.

## SEC filing metadata
- accession: 0001193125-25-051957
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312525051957/0001193125-25-051957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312525051957/d937567d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-051957
- JSON: https://secwatch.observer/filing/0001193125-25-051957.json
- Plain text: https://secwatch.observer/filing/0001193125-25-051957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.